CRC Research Update — June 04, 2026
Today's colorectal cancer research highlights
braf
A collection of 30 issues
CRC Research Update — June 01, 2026
Today's colorectal cancer research highlights
BRAF V600E triplet regimen advances in phase 3 trial
Skip to content
The CRC Digest
BRAF V600E triplet regimen advances in phase 3 trial
BREAKWATER Cohort 3 evaluated encorafenib + cetuximab + FOLFIRI versus FOLFIRI ± bevacizumab in previously untreated BRAF V600E-mutant mCRC, with primary endpoint of objective response rate and key secondary endpoint of progression-free survival. (Annals of Oncology)
This content
This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
CRC Research Update — May 25, 2026
Today's colorectal cancer research highlights
RAS/BRAF wild-type patients: Maintenance strategies compared
Skip to content
The CRC Digest
RAS/BRAF wild-type patients: Maintenance strategies compared
Three trials pooled data on left-sided, RAS/BRAF wild-type metastatic CRC to compare toxicity profiles of different maintenance approaches. (Journal of the National Cancer Institute)
This content is informational only and does not constitute medical advice.
Always
CRC Research Update — May 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 13, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer
Skip to content
The CRC Digest
Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer
A patient with BRAF V600E-mutant microsatellite-stable metastatic colorectal cancer achieved a prolonged response to pembrolizumab following a dynamic increase in tumor mutational burden. (The Oncologist)
This content is informational only and does not constitute